Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$90.78+9.10%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TARS
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | 606.3 | 451.4 | 183.0 | 17.4 | 25.8 | 57.0 | 0.0 |
| Total Revenues | 606.3 | 451.4 | 183.0 | 17.4 | 25.8 | 57.0 | 0.0 |
| Operating Expenses & Income | |||||||
| Selling, General & Admin | 526.4 | 427.3 | 237.3 | 108.7 | 44.9 | — | — |
| R&D Expenses | 87.7 | 64.3 | 53.4 | 50.3 | 42.6 | 41.7 | 18.8 |
| Operating Income | (48.5) | (71.0) | (120.6) | (143.2) | (62.7) | (12.2) | (27.0) |
| Earnings from Continuing Operations | |||||||
| Interest Expense | — | 8.9 | 7.8 | 3.3 | 2.2 | 0.0 | — |
| Other Non-Operating Income / Expenses | 9.2 | 6.6 | 5.0 | 7.3 | 0.6 | (1.6) | 0.2 |
| EBT, Incl. Unusual Items | — | (64.4) | (115.6) | (135.9) | (62.1) | (13.8) | (26.8) |
| Income Tax Expense | — | 2.1 | — | 0.0 | (0.0) | 0.1 | 0.0 |
| Net Income | |||||||
| Net Income | (46.1) | (66.4) | (115.6) | (136.0) | (62.1) | (13.8) | (26.8) |
| Per Share | |||||||
| Basic EPS | (1.06) | (1.59) | (3.07) | (4.62) | (2.52) | (0.67) | (4.32) |
| Diluted EPS | (1.06) | (1.59) | (3.07) | (4.62) | (2.52) | (0.67) | (4.32) |
| Revenue per Share | 13.97 | — | — | — | — | — | — |
| Dividend per Share | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Avg Shares | 43.4 | 41.8 | 37.6 | 29.4 | 24.6 | 20.6 | 6.2 |
| Diluted Weighted Avg Shares | 43.4 | 41.8 | 37.6 | 29.4 | 24.6 | 20.6 | 6.2 |
| Supplemental | |||||||
| EBIT | (48.5) | (71.0) | (120.6) | (143.2) | (62.7) | (12.2) | (27.0) |
| Effective Tax Rate | — | — | — | 0.0% | 0.0% | -0.4% | -0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.